INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17501, 27182, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17502, 27183, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17503, 27188, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17504, 27189, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17505, 27191, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17506, 27192, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17507, 27196, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17508, 27197, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17509, 27198, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17510, 27199, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17511, 27200, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17512, 27201, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17513, 27202, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17514, 27204, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17515, 27205, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17516, 27206, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17517, 27207, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17518, 32245, 'Potassium chloride', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17519, 2503, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17520, 5458, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17521, 7636, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17522, 8792, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17523, 9463, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17524, 10172, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17525, 10173, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17526, 10174, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17527, 10620, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17528, 10622, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17529, 10624, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17530, 10628, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17531, 10630, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17532, 10631, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17533, 15669, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17534, 23719, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17535, 24160, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17536, 24161, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17537, 24748, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17538, 25089, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17539, 25090, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17540, 25091, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17541, 25092, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17542, 25093, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17543, 26479, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17544, 27093, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17545, 27152, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17546, 27155, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17547, 27156, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17548, 27157, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17549, 27158, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17550, 27161, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17551, 27162, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17552, 27163, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17553, 27171, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17554, 27172, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17555, 27173, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17556, 27174, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17557, 27175, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17558, 27176, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17559, 27177, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17560, 27178, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17561, 27179, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17562, 27180, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17563, 27182, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17564, 27183, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17565, 27188, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17566, 27189, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17567, 27191, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17568, 27192, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17569, 27196, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17570, 27197, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17571, 27198, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17572, 27199, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17573, 27200, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17574, 27201, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17575, 27202, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17576, 27204, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17577, 27205, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17578, 27206, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17579, 27207, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17580, 32245, 'Potassium chloride', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17581, 2503, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17582, 5458, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17583, 7636, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17584, 8792, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17585, 9463, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17586, 10172, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17587, 10173, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17588, 10174, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17589, 10620, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17590, 10622, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17591, 10624, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17592, 10628, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17593, 10630, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17594, 10631, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17595, 15669, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17596, 23719, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17597, 24160, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17598, 24161, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17599, 24748, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17600, 25089, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17601, 25090, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17602, 25091, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17603, 25092, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17604, 25093, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17605, 26479, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17606, 27093, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17607, 27152, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17608, 27155, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17609, 27156, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17610, 27157, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17611, 27158, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17612, 27161, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17613, 27162, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17614, 27163, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17615, 27171, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17616, 27172, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17617, 27173, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17618, 27174, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17619, 27175, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17620, 27176, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17621, 27177, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17622, 27178, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17623, 27179, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17624, 27180, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17625, 27182, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17626, 27183, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17627, 27188, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17628, 27189, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17629, 27191, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17630, 27192, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17631, 27196, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17632, 27197, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17633, 27198, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17634, 27199, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17635, 27200, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17636, 27201, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17637, 27202, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17638, 27204, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17639, 27205, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17640, 27206, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17641, 27207, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17642, 32245, 'Potassium chloride', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17643, 2503, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17644, 5458, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17645, 7636, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17646, 8792, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17647, 9463, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17648, 10172, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17649, 10173, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17650, 10174, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17651, 10620, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17652, 10622, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17653, 10624, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17654, 10628, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17655, 10630, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17656, 10631, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17657, 15669, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17658, 23719, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17659, 24160, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17660, 24161, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17661, 24748, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17662, 25089, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17663, 25090, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17664, 25091, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17665, 25092, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17666, 25093, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17667, 26479, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17668, 27093, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17669, 27152, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17670, 27155, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17671, 27156, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17672, 27157, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17673, 27158, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17674, 27161, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17675, 27162, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17676, 27163, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17677, 27171, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17678, 27172, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17679, 27173, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17680, 27174, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17681, 27175, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17682, 27176, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17683, 27177, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17684, 27178, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17685, 27179, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17686, 27180, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17687, 27182, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17688, 27183, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17689, 27188, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17690, 27189, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17691, 27191, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17692, 27192, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17693, 27196, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17694, 27197, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17695, 27198, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17696, 27199, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17697, 27200, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17698, 27201, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17699, 27202, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17700, 27204, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17701, 27205, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17702, 27206, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17703, 27207, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17704, 32245, 'Potassium chloride', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17705, 2503, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17706, 5458, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17707, 7636, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17708, 8792, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17709, 9463, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17710, 10172, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17711, 10173, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17712, 10174, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17713, 10620, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17714, 10622, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17715, 10624, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17716, 10628, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17717, 10630, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17718, 10631, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17719, 15669, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17720, 23719, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17721, 24160, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17722, 24161, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17723, 24748, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17724, 25089, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17725, 25090, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17726, 25091, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17727, 25092, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17728, 25093, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17729, 26479, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17730, 27093, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17731, 27152, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17732, 27155, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17733, 27156, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17734, 27157, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17735, 27158, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17736, 27161, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17737, 27162, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17738, 27163, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17739, 27171, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17740, 27172, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17741, 27173, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17742, 27174, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17743, 27175, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17744, 27176, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17745, 27177, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17746, 27178, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17747, 27179, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17748, 27180, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17749, 27182, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17750, 27183, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17751, 27188, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17752, 27189, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17753, 27191, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17754, 27192, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17755, 27196, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17756, 27197, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17757, 27198, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17758, 27199, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17759, 27200, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17760, 27201, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17761, 27202, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17762, 27204, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17763, 27205, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17764, 27206, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17765, 27207, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17766, 32245, 'Potassium chloride', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988):  266-70|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17767, 23820, 'Posaconazole', 'Fructose Intolerance', 'Posaconazole powder for delayed-release oral suspension is contraindicated in patients with known/suspected hereditary fructose intolerance (HFI).  This formulation contains sorbitol (inactive ingredient) and may precipitate a metabolic crisis that may include (but is not limited to) life-threatening hypoglycemia, hypophosphatemia, lactic acidosis, and hepatic failure in patients with HFI.  Careful history of HFI symptoms (nausea, vomiting, abdominal pain) with sorbitol/fructose/sucrose exposure should be obtained before administration of posaconazole powder for delayed-release oral suspension because a diagnosis of HFI may not yet be established in pediatric patients.', '3', '"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17768, 23820, 'Posaconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17769, 23820, 'Posaconazole', 'Diarrhea', 'Patients with severe diarrhea or vomiting should be monitored closely for breakthrough fungal infections when using posaconazole delayed-release tablets, oral suspension, or powder for delayed-release oral suspension.', '2', '"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17770, 23820, 'Posaconazole', 'Water-Electrolyte Imbalance', 'Electrolyte disturbances (especially those involving potassium, magnesium, or calcium levels) should be monitored and corrected as needed before and during posaconazole therapy.', '2', '"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17771, 23820, 'Posaconazole', 'Liver Diseases', 'Posaconazole has been associated with hepatic reactions (e.g., mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin, and/or clinical hepatitis); cases of more severe hepatic reactions (including cholestasis or hepatic failure including deaths) have been reported during therapy in patients with serious underlying medical conditions (e.g., hematologic malignancy), primarily in patients receiving 800 mg/day.  Liver tests should be assessed at the start of and during posaconazole therapy; patients with abnormal liver tests during therapy should be monitored for the development of more severe hepatic injury.  Patient management should include laboratory evaluation of hepatic function (especially liver tests and bilirubin).  Discontinuation of therapy should be considered if clinical signs/symptoms consistent with liver disease develop that may be due to posaconazole.No dose adjustment of posaconazole is necessary in patients with mild to severe liver dysfunction (Child-Pugh A, B, or C).  However, posaconazole delayed-release tablets, powder for delayed-release oral suspension, and injection have not been specifically studied; caution is recommended.', '2', '"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17772, 23820, 'Posaconazole', 'Kidney Diseases', 'Posaconazole injection should be avoided in patients with moderate or severe renal dysfunction (estimated glomerular filtration rate [eGFR] less than 50 mL/min) unless an assessment of the risks and benefits justifies its use.  Since the IV vehicle, betadex sulfobutyl ether sodium (SBECD), is expected to accumulate in patients with moderate or severe renal dysfunction using the injection, serum creatinine levels should be closely monitored in these patients, and if increases occur, switching to oral posaconazole therapy should be considered.  No dose adjustment is needed for oral dosing in patients with mild to severe renal dysfunction; however, patients with severe renal dysfunction (eGFR less than 20 mL/min/1.73 m2) should be closely monitored for breakthrough fungal infections due to variability in exposure with posaconazole delayed-release tablets, oral suspension, and powder for delayed-release oral suspension.', '2', '"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17773, 6705, 'Potassium citrate', 'Urinary Tract Infections', 'The use of potassium citrate for management of renal tubular acidosis and renal stones is contraindicated in patients with active urinary tract infection caused by urea-splitting organisms.  Its ability to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate.  Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.', '3', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17774, 6961, 'Potassium citrate', 'Urinary Tract Infections', 'The use of potassium citrate for management of renal tubular acidosis and renal stones is contraindicated in patients with active urinary tract infection caused by urea-splitting organisms.  Its ability to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate.  Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.', '3', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17775, 16429, 'Potassium citrate', 'Urinary Tract Infections', 'The use of potassium citrate for management of renal tubular acidosis and renal stones is contraindicated in patients with active urinary tract infection caused by urea-splitting organisms.  Its ability to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate.  Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.', '3', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17776, 6705, 'Potassium citrate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17777, 6961, 'Potassium citrate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17778, 16429, 'Potassium citrate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17779, 6705, 'Potassium citrate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17780, 6961, 'Potassium citrate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17781, 16429, 'Potassium citrate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17782, 6705, 'Potassium citrate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17783, 6961, 'Potassium citrate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17784, 16429, 'Potassium citrate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17785, 6705, 'Potassium citrate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17786, 6961, 'Potassium citrate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17787, 16429, 'Potassium citrate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17788, 6705, 'Potassium citrate', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17789, 6961, 'Potassium citrate', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17790, 16429, 'Potassium citrate', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17791, 6705, 'Potassium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17792, 6961, 'Potassium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17793, 16429, 'Potassium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17794, 6705, 'Potassium citrate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Walker WG, Jost LJ "Relative roles of patassium and chloride in correction of hypokalemic hypochloremic alkalosis." Johns Hopkins Med J 120 (1967):  148-54|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17795, 6961, 'Potassium citrate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Walker WG, Jost LJ "Relative roles of patassium and chloride in correction of hypokalemic hypochloremic alkalosis." Johns Hopkins Med J 120 (1967):  148-54|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17796, 16429, 'Potassium citrate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Walker WG, Jost LJ "Relative roles of patassium and chloride in correction of hypokalemic hypochloremic alkalosis." Johns Hopkins Med J 120 (1967):  148-54|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17797, 202, 'Potassium gluconate', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17798, 202, 'Potassium gluconate', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17799, 202, 'Potassium gluconate', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', 'Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980):  69-71|Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989):  1083-91|Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973):  660-1|Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980):  485-6|Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978):  1339|Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976):  2125-6|Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988):  97-8,101-2|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975):  708-11|Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984):  270-1|Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986):  255-6|Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982):  546-7|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972):  156-68|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17800, 202, 'Potassium gluconate', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17801, 202, 'Potassium gluconate', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', 'Mason SJ, O''Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981):  115-20|Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987):  788-9|Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980):  23-5|Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967):  136-8|Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966):  97-101|Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967):  7-11|Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966):  291-6|Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965):  998-1001|Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971):  344|Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976):  495-6|Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965):  383-5|Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965):  492-3|Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973):  289-94|Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991):  1127-33|Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980):  508-11|Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986):  819-34|Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986):  192-4|Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966):  421-5|Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965):  745-9|Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983):  261-2|Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989):  855-6|Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987):  954-7|Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976):  698-9|Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970):  134-9|Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987):  490|Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979):  1673-6|Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977):  1124-5|Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975):  542|Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975):  206|Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965):  1409-12|Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965):  1546|Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974):  463-5|McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984):  852-5|Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn''s disease." Dig Dis Sci 31 (1986):  1387-90|Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965):  570|McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982):  1059-61|Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976):  251-2|Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976):  365|Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965):  1127|Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985):  453|Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  56-7|Hasker W, McCaffrey J "Ulceration of a Meckel''s diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972):  261-2|Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979):  377-9|Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974):  433-40|Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982):  1154-5|Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968):  76-80|Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967):  814-5|Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978):  542-3|Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984):  405-11|Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985):  273-8|Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967):  32-50,73-74,76-77|Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974):  143-4|Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980):  185-8,190|Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986):  157-63|Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986):  210-2|Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987):  206-9|Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969):  p315-8assim|Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976):  595-8|Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970):  518-23|Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983):  251-2|Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984):  392-7|Javett S "Slow k ulcer." S Afr J Surg 13 (1975):  64|Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965):  22|Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990):  420-4|Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994):  1268|"Potassium chloride and bowel ulceration." Br Med J 5475 (1965):  1383-4|McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985):  581-2|"Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965):  57-8|Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977):  111-2|"Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966):  138-41|"Product Information. K-Dur (potassium chloride)." Schering Corporation  (2001):|"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17802, 202, 'Potassium gluconate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', 'Walker WG, Jost LJ "Relative roles of patassium and chloride in correction of hypokalemic hypochloremic alkalosis." Johns Hopkins Med J 120 (1967):  148-54|"Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical  (2002):|"Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb  (2002):|"Product Information. Kaon (potassium gluconate)." Savage Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17803, 0, 'Pralidoxime', 'Myasthenia Gravis', 'Pralidoxime reactivates cholinesterase activity resulting in reduced levels of  acetylcholine and increased neuromuscular junction activity.  Treatment of organophosphate poisoning in patients myasthenia gravis with pralidoxime can precipitate a myasthenic crisis.', '3', '"Product Information. Protopam Chloride (pralidoxime)." Baxter Healthcare Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17804, 0, 'Pralidoxime', 'Kidney Diseases', 'Pralidoxime is eliminated by the kidney.  Approximately 80% to 90% of pralidoxime is excreted in the urine as unchanged drug.  The serum concentration of pralidoxime is increased in patients with renal impairment.  Therapy with pralidoxime should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal function and muscular activity is recommended.', '2', '"Product Information. Protopam Chloride (pralidoxime)." Baxter Healthcare Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17805, 3367, 'Potassium Iodide', 'Hyperthyroidism', 'The use of iodide salts has been associated with the exacerbation or precipitation of hyperthyroidism in patients previously euthyroid.  Induction of goiter has been reported in patients with hyperthyroidism.  Iodide salts should be administered cautiously in patients with hyperthyroidism.', '2', 'Iancu T, Boyanower Y, Laurian N "Congenital goiter due to maternal ingestion of iodide." Am J Dis Child 128 (1974):  528-30|Ayromlooi J "Congenital goiter due to maternal ingestion of iodides." Obstet Gynecol 39 (1972):  818-22|Denham MJ, Himsworth RL "Hyperthyroidism induced by potassium iodide given in the course of 125I-fibrinogen test." Age Ageing 3 (1974):  221-5|Yalow RS "Risks in mass distribution of potassium iodide." Bull N Y Acad Med 59 (1983):  1020-7|"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):|Carswell F, Kerr MM, Hutchison JH "Congenital goitre and hypothyroidism produced by maternal ingestion of iodides." Lancet 1 (1970):  1241-3|Parmelle A, et al. "Three cases of newborn infants with congential goiter due to ingestion of iodide." Am J Obstet Gynecol 40 (1940):  145-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17806, 25389, 'Potassium Iodide', 'Hyperthyroidism', 'The use of iodide salts has been associated with the exacerbation or precipitation of hyperthyroidism in patients previously euthyroid.  Induction of goiter has been reported in patients with hyperthyroidism.  Iodide salts should be administered cautiously in patients with hyperthyroidism.', '2', 'Iancu T, Boyanower Y, Laurian N "Congenital goiter due to maternal ingestion of iodide." Am J Dis Child 128 (1974):  528-30|Ayromlooi J "Congenital goiter due to maternal ingestion of iodides." Obstet Gynecol 39 (1972):  818-22|Denham MJ, Himsworth RL "Hyperthyroidism induced by potassium iodide given in the course of 125I-fibrinogen test." Age Ageing 3 (1974):  221-5|Yalow RS "Risks in mass distribution of potassium iodide." Bull N Y Acad Med 59 (1983):  1020-7|"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):|Carswell F, Kerr MM, Hutchison JH "Congenital goitre and hypothyroidism produced by maternal ingestion of iodides." Lancet 1 (1970):  1241-3|Parmelle A, et al. "Three cases of newborn infants with congential goiter due to ingestion of iodide." Am J Obstet Gynecol 40 (1940):  145-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17807, 3367, 'Potassium Iodide', 'Heart Diseases', 'Potassium iodide should not be used in patients that have nodular thyroid disease and heart disease.  Patients experiencing irregular heartbeats or chest pain should be instructed to stop treatment with potassium iodide.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17808, 25389, 'Potassium Iodide', 'Heart Diseases', 'Potassium iodide should not be used in patients that have nodular thyroid disease and heart disease.  Patients experiencing irregular heartbeats or chest pain should be instructed to stop treatment with potassium iodide.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17809, 3367, 'Potassium Iodide', 'Dermatitis Herpetiformis', 'Potassium iodide should not be used in patients that have or have ever had dermatitis herpetiformis.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17810, 25389, 'Potassium Iodide', 'Dermatitis Herpetiformis', 'Potassium iodide should not be used in patients that have or have ever had dermatitis herpetiformis.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17811, 3367, 'Potassium Iodide', 'Vasculitis', 'People who are allergic to iodide or have hypocomplementemic vasculitis should not take potassium iodide.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17812, 25389, 'Potassium Iodide', 'Vasculitis', 'People who are allergic to iodide or have hypocomplementemic vasculitis should not take potassium iodide.', '2', '"Product Information. SSKI (saturated) (potassium iodide)." Upsher-Smith Laboratories Inc|"Product Information. Pima (potassium iodide)." Fleming and Company  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17813, 1190, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17814, 1193, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17815, 5281, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17816, 6430, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17817, 14788, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17818, 14790, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17819, 14791, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17820, 14793, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17821, 17049, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17822, 32468, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17823, 32469, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17824, 32470, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', 'Lennard L, Van Loon JA, Weinshilboum RM "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism." Clin Pharmacol Ther 46 (1989):  149-54|DeClerck YA, Ettenger RB, Ortega JA, Pennisi AJ "Macrocytosis and pure RBC anemia caused by azathioprine." Am J Dis Child 134 (1980):  377-9|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Nossent JC, Swaak AJ "Pancytopenia in systemic lupus erythematosus related to azathioprine." J Intern Med 227 (1990):  69-72|Hogge DE, Wilson DR, Shumak KH, Cattran DC "Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient." Can Med Assoc J 126 (1982):  512-3|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Jeurissen ME, Boerbooms AM, Van de Putte LB "Pancytopenia related to azathioprine in rheumatoid arthritis." Ann Rheum Dis 47 (1988):  503-5|Speerstra F, Boerbooms AM, van de Putte LB, et al. "Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience." Ann Rheum Dis 41 (1982):  37-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Anstey A, Lennard L, Mayou SC, Kirby JD "Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review." J R Soc Med 85 (1992):  752-6|Creemers GJ, van Boven WP, Lowenberg B, van der Heul C "Azathioprine-associated pure red cell aplasia." J Intern Med 233 (1993):  85-7|Agarwal SK, Mittal D, Tiwari SC, Dash SC, Saxena S, Saxena R, Mehta SN "Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient." Nephron 63 (1993):  471|Kerstens PJ, Stolk JN, Hilbrands LB, Vandeputte LB, Deabreu RA, Boerbooms AM "5-nucleotidase and azathioprine-related bone-marrow toxicity." Lancet 342 (1993):  1245-6|Kerstens PJSM, Stolk JN, Deabreu RA, Lambooy LHJ, Vandeputte LBA, Boerbooms AAMT "Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis." Arthritis Rheum 38 (1995):  142-5|Snow JL, Gibson LE "A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients." J Am Acad Dermatol 32 (1995):  114-6|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17825, 1190, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17826, 1193, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17827, 5281, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17828, 6430, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17829, 14788, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17830, 14790, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17831, 14791, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17832, 14793, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17833, 17049, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17834, 32468, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17835, 32469, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17836, 32470, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17837, 1190, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17838, 1193, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17839, 5281, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17840, 6430, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17841, 14788, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17842, 14790, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17843, 14791, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17844, 14793, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17845, 17049, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17846, 32468, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17847, 32469, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17848, 32470, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', 'Duttera MJ, Carolla RL, Gallelli JF, et al. "Hematuria and crystalluria after high-dose 6-mercaptopurine administration." N Engl J Med 287 (1972):  292-4|Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC "Pharmacokinetics of azathioprine under haemodialysis." Int J Clin Pharmacol 14 (1976):  298-302|Ding TL, Gambertoglio JG, Amend JC, et al. "Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients." Clin Pharmacol Ther 27 (1980):  250|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Keystone EC, Schabas R "Hypotension with oliguria: a side-effect of azathioprine." Arthritis Rheum 24 (1981):  1453-4|Trotta F, Menegale G, Fiocchi O "Azathioprine-induced hypotension with oliguria." Arthritis Rheum 25 (1982):  1388-9|Whisnant JK, Pelkey J "Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)): clinical side-effects and laboratory abnormalities." Ann Rheum Dis 41 (1982):  44-7|Chan GL, Erdmann GR, Gruber SA, et al. "Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine." Eur J Clin Pharmacol 36 (1989):  265-71|Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Grefberg N "Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients." Int J Immunopharmacol 8 (1986):  1-11|Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM "Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients." J Clin Pharmacol 30 (1990):  358-63|McHenry PM, Allan JG, Rodger RS, Lever RS "Nephrotoxicity due to azathioprine." Br J Dermatol 128 (1993):  106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17849, 1190, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17850, 1193, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17851, 5281, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17852, 6430, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17853, 14788, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17854, 14790, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17855, 14791, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17856, 14793, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17857, 17049, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17858, 32468, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17859, 32469, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17860, 32470, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', 'Millard PR, Herbertson BM, Evans DB, Calne RY "Azathioprine hepatotoxicity in renal transplantation." Transplantation 16 (1973):  527-30|Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D "Hyperplasie nodulaire regenerative du foie associee a la prise d''azathioprine." Gastroenterol Clin Biol 15 (1991):  968-73|Sterneck M, Wiesner R, Ascher N, et al. "Azathioprine hepatotoxicity after liver transplantation." Hepatology 14 (1991):  806-10|Farge D, Parfrey PS, Forbes RD, Dandavino R, Guttmann RD "Reduction of azathioprine in renal transplant patients with chronic hepatitis." Transplantation 41 (1986):  55-9|Gerlag PG, van Hooff JP "Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation." Transplant Proc 19 (1987):  3699-703|Liano F, Moreno A, Matesanz R, et al. "Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?" Nephron 51 (1989):  509-16|Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV "Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis." Neurology 38 (1988):  258-61|Cooper C, Minihane N, Cotton DW, Cawley MI "Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis." J R Soc Med 79 (1986):  171-3|Katska DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD "Azathioprine and hepatic venocclusive disease in renal transplant patients." Gastroenterology 90 (1986):  446-54|DePinho RA, Goldberg CS, Lefkowitch JH "Azathioprine and the liver: evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans." Gastroenterology 86 (1984):  162-5|Singh G, Fries JF, Spitz P, Williams CA "Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective." Arthritis Rheum 32 (1989):  837-43|Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ "Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis." Ann Rheum Dis 48 (1989):  342-6|Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW "Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis." Ann Rheum Dis 49 (1990):  25-7|Read AE, Wiesner RH, LaBrecque DR, et al. "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy." Ann Intern Med 104 (1986):  651-5|Small P, Lichter M "Probably azathioprine hepatotoxicity: a case report." Ann Allergy 62 (1989):  518-20|"Product Information. Imuran (azathioprine)." Glaxo Wellcome  (2002):|Meys E, Devogelaer JP, Geubel A, Rahier J, de Deuxchaisnes CN "Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity." J Rheumatol 19 (1992):  807-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17861, 0, 'Plecanatide', 'Dehydration', 'Plecanatide should be used with caution in dehydrated patients and patients with severe diarrhea.  Plecanatide is contraindicated in patients less than 6 years of age as these patients may be more likely to develop severe diarrhea and its potentially serious consequences.  Care is recommended when using this agent in adult patients with electrolyte abnormalities or with severe diarrhea.  It is recommended to suspend dosing and rehydrate the patient if such symptoms occur during therapy.', '3', '"Product Information. Trulance (plecanatide)." Synergy Pharmaceuticals Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17862, 0, 'Plecanatide', 'Intestinal Obstruction', 'The use of plecanatide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.', '3', '"Product Information. Trulance (plecanatide)." Synergy Pharmaceuticals Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17863, 2559, 'Acetazolamide', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', 'Keisu M, Wiholm BE, Ost A, Mortimer O "Acetazolamide-associated aplastic anaemia." J Intern Med 228 (1990):  627-32|Gangitano JL, Foster SH, Contro RM "Nonfatal methazolamide-induced aplastic anemia." Am J Ophthalmol 86 (1978):  138-9|Wisch N, Fischbein FI, Siegel R, Glass JL, Leopold I "Aplastic anemia resulting from the use of carbonic anhydrase inhibitors." Am J Ophthalmol 75 (1973):  130-2|Lubeck MJ "Aplastic anemia following acetazolamide therapy." Am J Ophthalmol 69 (1970):  684-5|Kristinsson A "Fatal reaction to acetazolamide." Br J Ophthalmol 51 (1967):  348-9|Englund GW "Fatal pancytopenia and acetazolamide therapy." JAMA 210 (1969):  2282|Rentiers PK, Johnston AC, Buskard N "Severe aplastic anemia as a complication of acetazolamide therapy." Can J Ophthalmol 5 (1970):  337-42|McWhae JA, Chang J, Lipton JH "Drug-induced fatal aplastic anemia following cataract surgery." Can J Ophthalmol 27 (1992):  313-5|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17864, 3601, 'Acetazolamide', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', 'Keisu M, Wiholm BE, Ost A, Mortimer O "Acetazolamide-associated aplastic anaemia." J Intern Med 228 (1990):  627-32|Gangitano JL, Foster SH, Contro RM "Nonfatal methazolamide-induced aplastic anemia." Am J Ophthalmol 86 (1978):  138-9|Wisch N, Fischbein FI, Siegel R, Glass JL, Leopold I "Aplastic anemia resulting from the use of carbonic anhydrase inhibitors." Am J Ophthalmol 75 (1973):  130-2|Lubeck MJ "Aplastic anemia following acetazolamide therapy." Am J Ophthalmol 69 (1970):  684-5|Kristinsson A "Fatal reaction to acetazolamide." Br J Ophthalmol 51 (1967):  348-9|Englund GW "Fatal pancytopenia and acetazolamide therapy." JAMA 210 (1969):  2282|Rentiers PK, Johnston AC, Buskard N "Severe aplastic anemia as a complication of acetazolamide therapy." Can J Ophthalmol 5 (1970):  337-42|McWhae JA, Chang J, Lipton JH "Drug-induced fatal aplastic anemia following cataract surgery." Can J Ophthalmol 27 (1992):  313-5|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17865, 2559, 'Acetazolamide', 'Adrenal Insufficiency', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency.  The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients.  Monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17866, 3601, 'Acetazolamide', 'Adrenal Insufficiency', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency.  The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients.  Monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17867, 2559, 'Acetazolamide', 'Glaucoma, Angle-Closure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma.  Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure.  Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.', '3', 'Fan JT, Johnson DH, Burk RR "Transient myopia, angle-closure glaucoma, and choroidal detachment after oral acetazolamide." Am J Ophthalmol 115 (1993):  813-4|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17868, 3601, 'Acetazolamide', 'Glaucoma, Angle-Closure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma.  Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure.  Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.', '3', 'Fan JT, Johnson DH, Burk RR "Transient myopia, angle-closure glaucoma, and choroidal detachment after oral acetazolamide." Am J Ophthalmol 115 (1993):  813-4|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17869, 2559, 'Acetazolamide', 'Hypokalemia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia .  Carbonic anhydrase inhibitors may cause increased potassium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', 'Torres CF, Griggs RC, Moxley RT, Bender AN "Hypokalemic periodic paralysis exacerbated by acetazolamide." Neurology 31 (1981):  1423-8|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17870, 3601, 'Acetazolamide', 'Hypokalemia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia .  Carbonic anhydrase inhibitors may cause increased potassium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', 'Torres CF, Griggs RC, Moxley RT, Bender AN "Hypokalemic periodic paralysis exacerbated by acetazolamide." Neurology 31 (1981):  1423-8|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17871, 2559, 'Acetazolamide', 'Hyponatremia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia .  Carbonic anhydrase inhibitors may cause sodium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17872, 3601, 'Acetazolamide', 'Hyponatremia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia .  Carbonic anhydrase inhibitors may cause sodium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17873, 2559, 'Acetazolamide', 'Kidney Diseases', 'The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease.  Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.', '3', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|De Marchi S, Cecchin E "Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis." Clin Sci 78 (1990):  295-302|Korzets A, Gafter U, Floru S, Chagnac A, Zevin D "Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri." Am J Kidney Dis 21 (1993):  322-4|Parfitt AM "Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis: relationship to citrate and calcium excretion." Arch Intern Med 124 (1969):  736-40|Tawil R, Moxley RT 3d, Griggs RC "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders." Neurology 43 (1993):  1105-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|Parikh JR, Nolan RL, Bannerjee A, Gault MH "Acetazolamide-associated nephrocalcinosis in a transplant kidney." Transplantation 59 (1995):  1742-3|Schwenk MH, Stpeter WL, Meese MG, Singhal PC "Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis." Pharmacotherapy 15 (1995):  522-7|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17874, 3601, 'Acetazolamide', 'Kidney Diseases', 'The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease.  Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.', '3', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|De Marchi S, Cecchin E "Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis." Clin Sci 78 (1990):  295-302|Korzets A, Gafter U, Floru S, Chagnac A, Zevin D "Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri." Am J Kidney Dis 21 (1993):  322-4|Parfitt AM "Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis: relationship to citrate and calcium excretion." Arch Intern Med 124 (1969):  736-40|Tawil R, Moxley RT 3d, Griggs RC "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders." Neurology 43 (1993):  1105-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|Parikh JR, Nolan RL, Bannerjee A, Gault MH "Acetazolamide-associated nephrocalcinosis in a transplant kidney." Transplantation 59 (1995):  1742-3|Schwenk MH, Stpeter WL, Meese MG, Singhal PC "Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis." Pharmacotherapy 15 (1995):  522-7|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17875, 2559, 'Acetazolamide', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', 'Maren TH "Acetazolamide and advanced liver disease ." Am J Ophthalmol 102 (1986):  672-3|Margo CE "Acetazolamide and advanced liver disease." Am J Ophthalmol 101 (1986):  611-2|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17876, 3601, 'Acetazolamide', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', 'Maren TH "Acetazolamide and advanced liver disease ." Am J Ophthalmol 102 (1986):  672-3|Margo CE "Acetazolamide and advanced liver disease." Am J Ophthalmol 101 (1986):  611-2|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17877, 2559, 'Acetazolamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', 'Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17878, 3601, 'Acetazolamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', 'Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17879, 2559, 'Acetazolamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17880, 3601, 'Acetazolamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', 'Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991):  457-64|Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979):  284-6|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17881, 2559, 'Acetazolamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', 'Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969):  145-7|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17882, 3601, 'Acetazolamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', 'Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969):  145-7|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17883, 2559, 'Acetazolamide', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', 'Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Heller I, Halevy J, Cohen S, Theodor E "Significant metabolic acidosis induced by acetazolamide: not a rare complication." Arch Intern Med 145 (1985):  1815-7|Gabay EL "Metabolic acidosis from acetazolamide therapy ." Arch Ophthalmol 101 (1983):  303-4|Berthelsen P "Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis." Intensive Care Med 8 (1982):  269-74|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17884, 3601, 'Acetazolamide', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', 'Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  1114|Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982):  422|Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981):  1527-8|Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63|Heller I, Halevy J, Cohen S, Theodor E "Significant metabolic acidosis induced by acetazolamide: not a rare complication." Arch Intern Med 145 (1985):  1815-7|Gabay EL "Metabolic acidosis from acetazolamide therapy ." Arch Ophthalmol 101 (1983):  303-4|Berthelsen P "Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis." Intensive Care Med 8 (1982):  269-74|"Product Information. Diamox (acetazolamide)." Lederle Laboratories  (2001):|"Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17885, 19302, 'Pralatrexate', 'Liver Failure', 'The safety, efficacy and pharmacokinetics of pralatrexate have not been evaluated in patients with hepatic impairment.  Additionally, this drug can cause hepatotoxicity and liver function test abnormalities, which might require dose modification or discontinuation.  Caution and monitoring is advised.', '2', '"Product Information. Folotyn (pralatrexate)." Allos Therapeutics  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17886, 19302, 'Pralatrexate', 'Kidney Diseases', 'Patients with moderate to severe renal function impairment may be at greater risk of toxicity due to increased exposure.  Patients should be monitored for renal function and toxicity and dosage should be adjusted accordingly.  For patients with severe renal impairment (GFR 15 to <30), the recommended dose of pralatrexate is 15 mg/m2.  Avoid the use of pralatrexate in patients with ESRD undergoing dialysis, unless the potential effect justifies the potential risk.', '2', '"Product Information. Folotyn (pralatrexate)." Allos Therapeutics  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17887, 0, 'Prasugrel', 'Hemorrhage', 'Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.', '3', '"Product Information. Effient (prasugrel)." Lilly, Eli and Company  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17888, 0, 'Prasugrel', 'Coronary Artery Disease', 'Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke.  Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued.  The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft.  If possible, prasugrel should be discontinued at least 7 days prior to the procedure.', '3', '"Product Information. Effient (prasugrel)." Lilly, Eli and Company  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17889, 0, 'Prasugrel', 'Liver Diseases', 'No dosage adjustment is necessary for patients with renal impairment.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.  Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.', '2', '"Product Information. Effient (prasugrel)." Lilly, Eli and Company  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17890, 7403, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Arnon R, Eisenberg S "Lovastatin-induced hepatitis." Isr J Med Sci 28 (1992):  101-2|Mauro VF "Clinical pharmacokinetics and practical applications of simvastatin." Clin Pharmacokinet 24 (1993):  195-202|Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991):  257-64|Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S "The physiological disposition of lovastatin." Drug Metab Dispos 17 (1989):  166-73|Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD "Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans." J Clin Pharmacol 32 (1992):  136-40|Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH "Biotransformation of pravastatin sodium in humans." Drug Metab Dispos 19 (1991):  740-8|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Geddes JA "Cholestatic jaundice associated with lovastatin (mevacor) therapy." Can Med Assoc J 143 (1990):  13-4|McQueen MJ "Cholestatic jaundice associated with lovastatin (Mevacor) therapy." Can Med Assoc J 142 (1990):  841-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ "Biotransformation of fluvastatin sodium in humans." Drug Metab Dispos 21 (1993):  567-72|Tse FL, Jaffe JM, Troendle A "Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers." J Clin Pharmacol 32 (1992):  630-8|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE "Biotransformation of lovastatin .5. species differences in invivo metabolite profiles of mouse, rat, dog, and human." Drug Metab Dispos 21 (1993):  1003-11|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Davidson MH, on behalf of the FLUENT Investigators Group "Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety." Am J Med 96 Suppl (1994):  96 (suppl)|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Grimbert S, Pessayre D, Degott C, Benhamou JP "Acute hepatitis induced by HMG-coa reductase inhibitor, lovastatin." Dig Dis Sci 39 (1994):  2032-3|Smit JW, Wijnne HJ, Schobben F, Sitsen A, Debruin TW, Erkelens DW "Effects of alcohol and fluvastatin on lipid metabolism and hepatic function." Ann Intern Med 122 (1995):  678-80|Smit JWA, Wijnne HJA, Schobben F, Sitsen A, Debruin TWA, Erkelens DW "Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin." Am J Cardiol 76 (1995):  a89-96|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997):  321-31|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL "Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects." Clin Pharmacol Ther 60 (1996):  687-95|Lea AP, McTavish D "Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias." Drugs 53 (1997):  828-47|Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning an evening." J Clin Pharmacol 36 (1996):  604-9|Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ "Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects." J Clin Pharmacol 36 (1996):  728-31|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Muck W, Unger S, Kawano K, Ahr G "Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin." Br J Clin Pharmacol 45 (1998):  583-90|Hartleb M, Rymarczyk G, Januszewski K "Acute cholestatic hepatitis associated with pravastatin." Am J Gastroenterol 94 (1999):  1388-90|Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999):  1763-4|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17891, 7405, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Arnon R, Eisenberg S "Lovastatin-induced hepatitis." Isr J Med Sci 28 (1992):  101-2|Mauro VF "Clinical pharmacokinetics and practical applications of simvastatin." Clin Pharmacokinet 24 (1993):  195-202|Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991):  257-64|Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S "The physiological disposition of lovastatin." Drug Metab Dispos 17 (1989):  166-73|Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD "Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans." J Clin Pharmacol 32 (1992):  136-40|Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH "Biotransformation of pravastatin sodium in humans." Drug Metab Dispos 19 (1991):  740-8|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Geddes JA "Cholestatic jaundice associated with lovastatin (mevacor) therapy." Can Med Assoc J 143 (1990):  13-4|McQueen MJ "Cholestatic jaundice associated with lovastatin (Mevacor) therapy." Can Med Assoc J 142 (1990):  841-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ "Biotransformation of fluvastatin sodium in humans." Drug Metab Dispos 21 (1993):  567-72|Tse FL, Jaffe JM, Troendle A "Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers." J Clin Pharmacol 32 (1992):  630-8|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE "Biotransformation of lovastatin .5. species differences in invivo metabolite profiles of mouse, rat, dog, and human." Drug Metab Dispos 21 (1993):  1003-11|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Davidson MH, on behalf of the FLUENT Investigators Group "Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety." Am J Med 96 Suppl (1994):  96 (suppl)|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Grimbert S, Pessayre D, Degott C, Benhamou JP "Acute hepatitis induced by HMG-coa reductase inhibitor, lovastatin." Dig Dis Sci 39 (1994):  2032-3|Smit JW, Wijnne HJ, Schobben F, Sitsen A, Debruin TW, Erkelens DW "Effects of alcohol and fluvastatin on lipid metabolism and hepatic function." Ann Intern Med 122 (1995):  678-80|Smit JWA, Wijnne HJA, Schobben F, Sitsen A, Debruin TWA, Erkelens DW "Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin." Am J Cardiol 76 (1995):  a89-96|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997):  321-31|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL "Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects." Clin Pharmacol Ther 60 (1996):  687-95|Lea AP, McTavish D "Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias." Drugs 53 (1997):  828-47|Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning an evening." J Clin Pharmacol 36 (1996):  604-9|Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ "Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects." J Clin Pharmacol 36 (1996):  728-31|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Muck W, Unger S, Kawano K, Ahr G "Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin." Br J Clin Pharmacol 45 (1998):  583-90|Hartleb M, Rymarczyk G, Januszewski K "Acute cholestatic hepatitis associated with pravastatin." Am J Gastroenterol 94 (1999):  1388-90|Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999):  1763-4|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17892, 16265, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Arnon R, Eisenberg S "Lovastatin-induced hepatitis." Isr J Med Sci 28 (1992):  101-2|Mauro VF "Clinical pharmacokinetics and practical applications of simvastatin." Clin Pharmacokinet 24 (1993):  195-202|Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991):  257-64|Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S "The physiological disposition of lovastatin." Drug Metab Dispos 17 (1989):  166-73|Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD "Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans." J Clin Pharmacol 32 (1992):  136-40|Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH "Biotransformation of pravastatin sodium in humans." Drug Metab Dispos 19 (1991):  740-8|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Geddes JA "Cholestatic jaundice associated with lovastatin (mevacor) therapy." Can Med Assoc J 143 (1990):  13-4|McQueen MJ "Cholestatic jaundice associated with lovastatin (Mevacor) therapy." Can Med Assoc J 142 (1990):  841-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ "Biotransformation of fluvastatin sodium in humans." Drug Metab Dispos 21 (1993):  567-72|Tse FL, Jaffe JM, Troendle A "Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers." J Clin Pharmacol 32 (1992):  630-8|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE "Biotransformation of lovastatin .5. species differences in invivo metabolite profiles of mouse, rat, dog, and human." Drug Metab Dispos 21 (1993):  1003-11|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Davidson MH, on behalf of the FLUENT Investigators Group "Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety." Am J Med 96 Suppl (1994):  96 (suppl)|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Grimbert S, Pessayre D, Degott C, Benhamou JP "Acute hepatitis induced by HMG-coa reductase inhibitor, lovastatin." Dig Dis Sci 39 (1994):  2032-3|Smit JW, Wijnne HJ, Schobben F, Sitsen A, Debruin TW, Erkelens DW "Effects of alcohol and fluvastatin on lipid metabolism and hepatic function." Ann Intern Med 122 (1995):  678-80|Smit JWA, Wijnne HJA, Schobben F, Sitsen A, Debruin TWA, Erkelens DW "Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin." Am J Cardiol 76 (1995):  a89-96|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997):  321-31|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL "Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects." Clin Pharmacol Ther 60 (1996):  687-95|Lea AP, McTavish D "Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias." Drugs 53 (1997):  828-47|Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning an evening." J Clin Pharmacol 36 (1996):  604-9|Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ "Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects." J Clin Pharmacol 36 (1996):  728-31|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Muck W, Unger S, Kawano K, Ahr G "Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin." Br J Clin Pharmacol 45 (1998):  583-90|Hartleb M, Rymarczyk G, Januszewski K "Acute cholestatic hepatitis associated with pravastatin." Am J Gastroenterol 94 (1999):  1388-90|Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999):  1763-4|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17893, 21898, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Arnon R, Eisenberg S "Lovastatin-induced hepatitis." Isr J Med Sci 28 (1992):  101-2|Mauro VF "Clinical pharmacokinetics and practical applications of simvastatin." Clin Pharmacokinet 24 (1993):  195-202|Mauro VF, MacDonald JL "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991):  257-64|Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S "The physiological disposition of lovastatin." Drug Metab Dispos 17 (1989):  166-73|Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD "Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans." J Clin Pharmacol 32 (1992):  136-40|Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH "Biotransformation of pravastatin sodium in humans." Drug Metab Dispos 19 (1991):  740-8|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Geddes JA "Cholestatic jaundice associated with lovastatin (mevacor) therapy." Can Med Assoc J 143 (1990):  13-4|McQueen MJ "Cholestatic jaundice associated with lovastatin (Mevacor) therapy." Can Med Assoc J 142 (1990):  841-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ "Biotransformation of fluvastatin sodium in humans." Drug Metab Dispos 21 (1993):  567-72|Tse FL, Jaffe JM, Troendle A "Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers." J Clin Pharmacol 32 (1992):  630-8|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE "Biotransformation of lovastatin .5. species differences in invivo metabolite profiles of mouse, rat, dog, and human." Drug Metab Dispos 21 (1993):  1003-11|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Davidson MH, on behalf of the FLUENT Investigators Group "Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety." Am J Med 96 Suppl (1994):  96 (suppl)|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Grimbert S, Pessayre D, Degott C, Benhamou JP "Acute hepatitis induced by HMG-coa reductase inhibitor, lovastatin." Dig Dis Sci 39 (1994):  2032-3|Smit JW, Wijnne HJ, Schobben F, Sitsen A, Debruin TW, Erkelens DW "Effects of alcohol and fluvastatin on lipid metabolism and hepatic function." Ann Intern Med 122 (1995):  678-80|Smit JWA, Wijnne HJA, Schobben F, Sitsen A, Debruin TWA, Erkelens DW "Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin." Am J Cardiol 76 (1995):  a89-96|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997):  321-31|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL "Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects." Clin Pharmacol Ther 60 (1996):  687-95|Lea AP, McTavish D "Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias." Drugs 53 (1997):  828-47|Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning an evening." J Clin Pharmacol 36 (1996):  604-9|Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ "Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects." J Clin Pharmacol 36 (1996):  728-31|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Muck W, Unger S, Kawano K, Ahr G "Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin." Br J Clin Pharmacol 45 (1998):  583-90|Hartleb M, Rymarczyk G, Januszewski K "Acute cholestatic hepatitis associated with pravastatin." Am J Gastroenterol 94 (1999):  1388-90|Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999):  1763-4|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17894, 7403, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Schalke BB, Schmidt B, Toyka K, Hartung H-P "Pravastatin-associated inflammatory myopathy." N Engl J Med 327 (1992):  649-50|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|Reaven P, Witztum JL "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med 109 (1988):  597-8|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988):  239-41|East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988):  47-8|Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988):  46-7|Wallace CS, Mueller BA "Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs." Ann Pharmacother 26 (1992):  190-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993):  109-10|McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993):  647-8|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Fernandezzatarain G, Navarro V, Garcia H, Villatoro J, Calvo C "Rhabdomyolysis and acute renal failure associated with lovastatin." Nephron 66 (1994):  483-4|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995):  664-5|Ahmand S "Lovastatin-induced myopathy in a hypothyroid patient." J Fam Pract 41 (1995):  227-8|Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996):  2085-92|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997):  859-63|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998):  654-5|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17895, 7405, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Schalke BB, Schmidt B, Toyka K, Hartung H-P "Pravastatin-associated inflammatory myopathy." N Engl J Med 327 (1992):  649-50|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|Reaven P, Witztum JL "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med 109 (1988):  597-8|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988):  239-41|East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988):  47-8|Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988):  46-7|Wallace CS, Mueller BA "Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs." Ann Pharmacother 26 (1992):  190-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993):  109-10|McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993):  647-8|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Fernandezzatarain G, Navarro V, Garcia H, Villatoro J, Calvo C "Rhabdomyolysis and acute renal failure associated with lovastatin." Nephron 66 (1994):  483-4|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995):  664-5|Ahmand S "Lovastatin-induced myopathy in a hypothyroid patient." J Fam Pract 41 (1995):  227-8|Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996):  2085-92|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997):  859-63|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998):  654-5|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17896, 16265, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Schalke BB, Schmidt B, Toyka K, Hartung H-P "Pravastatin-associated inflammatory myopathy." N Engl J Med 327 (1992):  649-50|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|Reaven P, Witztum JL "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med 109 (1988):  597-8|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988):  239-41|East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988):  47-8|Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988):  46-7|Wallace CS, Mueller BA "Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs." Ann Pharmacother 26 (1992):  190-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993):  109-10|McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993):  647-8|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Fernandezzatarain G, Navarro V, Garcia H, Villatoro J, Calvo C "Rhabdomyolysis and acute renal failure associated with lovastatin." Nephron 66 (1994):  483-4|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995):  664-5|Ahmand S "Lovastatin-induced myopathy in a hypothyroid patient." J Fam Pract 41 (1995):  227-8|Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996):  2085-92|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997):  859-63|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998):  654-5|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17897, 21898, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Schalke BB, Schmidt B, Toyka K, Hartung H-P "Pravastatin-associated inflammatory myopathy." N Engl J Med 327 (1992):  649-50|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989):  s44-6|Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993):  317-22|McGovern ME, Mellies MJ "Long-term experience with pravastatin in clinical research trials." Clin Ther 15 (1993):  57-64|Reaven P, Witztum JL "Lovastatin, nicotinic acid, and rhabdomyolysis." Ann Intern Med 109 (1988):  597-8|"Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV." Arch Intern Med 153 (1993):  1079-87|Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988):  239-41|East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988):  47-8|Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988):  46-7|Wallace CS, Mueller BA "Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs." Ann Pharmacother 26 (1992):  190-2|Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990):  58-65|"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993):  109-10|McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993):  647-8|Levy RI, Troendle AJ, Fattu JM "A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin." Circulation 87 (1993):  i45-53|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|Fernandezzatarain G, Navarro V, Garcia H, Villatoro J, Calvo C "Rhabdomyolysis and acute renal failure associated with lovastatin." Nephron 66 (1994):  483-4|Jokubaitis LA "Updated clinical safety experience with fluvastatin." Am J Cardiol 73 (1994):  d18-24|Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995):  664-5|Ahmand S "Lovastatin-induced myopathy in a hypothyroid patient." J Fam Pract 41 (1995):  227-8|Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996):  2085-92|Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia." JAMA 275 (1996):  128-33|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|"Product Information. Baycol (cerivastatin)." Bayer  (2001):|Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997):  859-63|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Alvarez JM, Rawdanowiz TJ, Goldstein J "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998):  654-5|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17898, 7403, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H "Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment." J Clin Pharmacol 32 (1992):  124-32|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Sigurbjornsson S, Kjartansdottir T, Johannsson M, Kristinsson J, Sigurdsson G "A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers." Eur J Drug Metab Pharmacokinet 23 (1998):  13-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17899, 7405, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H "Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment." J Clin Pharmacol 32 (1992):  124-32|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Sigurbjornsson S, Kjartansdottir T, Johannsson M, Kristinsson J, Sigurdsson G "A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers." Eur J Drug Metab Pharmacokinet 23 (1998):  13-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17900, 16265, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H "Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment." J Clin Pharmacol 32 (1992):  124-32|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Sigurbjornsson S, Kjartansdottir T, Johannsson M, Kristinsson J, Sigurdsson G "A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers." Eur J Drug Metab Pharmacokinet 23 (1998):  13-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17901, 21898, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', 'Pan HY, DeValut AR, Wang-Iverson D, et al. "Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin." J Clin Pharmacol 30 (1990):  1128-35|Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H "Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment." J Clin Pharmacol 32 (1992):  124-32|Pan HY, Morrison RA, Singhvi SM, Frantz BM, Waclawski AP, Willard DA "Disposition of pravastatin sodium (SQ 31,000), a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects." Clin Res 36 (1988):  a368|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|Quion JAV, Jones PH "Clinical pharmacokinetics of pravastatin." Clin Pharmacokinet 27 (1994):  94-103|Lennernas H, Fager G "Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences." Clin Pharmacokinet 32 (1997):  403-25|Sigurbjornsson S, Kjartansdottir T, Johannsson M, Kristinsson J, Sigurdsson G "A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers." Eur J Drug Metab Pharmacokinet 23 (1998):  13-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17902, 7403, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17903, 7405, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17904, 16265, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17905, 21898, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17906, 7403, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17907, 7405, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17908, 16265, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17909, 21898, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '"Product Information. Mevacor (lovastatin)." Merck & Co., Inc  (2002):|"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb  (2001):|"Product Information. Zocor (simvastatin)." Merck & Co., Inc  (2001):|"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals  (2001):|"Product Information. Lipitor (atorvastatin)." Parke-Davis  (2001):|"Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc  (2003):|"Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17910, 13086, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17911, 17831, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17912, 17832, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17913, 21425, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17914, 25669, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17915, 26928, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17916, 26929, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17917, 27124, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17918, 27125, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17919, 13086, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17920, 17831, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17921, 17832, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17922, 21425, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17923, 25669, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17924, 26928, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17925, 26929, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17926, 27124, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17927, 27125, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17928, 13086, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17929, 17831, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17930, 17832, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17931, 21425, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17932, 25669, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17933, 26928, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17934, 26929, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17935, 27124, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17936, 27125, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17937, 13086, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17938, 17831, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17939, 17832, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17940, 21425, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17941, 25669, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17942, 26928, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17943, 26929, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17944, 27124, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17945, 27125, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', 'Wright CE, Sisson TL, Ichhpurani AK, Peters GR "Steady-state pharmacokinetic properties of pramipexole in healthy volunteers." J Clin Pharmacol 37 (1997):  520-5|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17946, 0, 'Pramlintide', 'Gastroparesis', 'The use of pramlintide is contraindicated in patients with a confirmed diagnosis of gastroparesis as it slows gastric emptying.', '3', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17947, 1510, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17948, 15194, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17949, 15198, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17950, 17726, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17951, 18443, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17952, 25135, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17953, 25136, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17954, 25137, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17955, 26607, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', 'Markwalder K, Hess K, Valavanis A, Witassek F "Cerebral cysticercosis: treatment with praziquantel. Report of two cases." Am J Trop Med Hyg 33 (1984):  273-80|Bada JL, Trevino B, Cabezos J "Convulsive seizures after treatment with praziquantel." Br Med J (Clin Res Ed) 296 (1988):  646|Flisser A, Madrazo I, Plancarte A, Schantz P, Allan J, Craig P, Sarti E "Neurological symptoms in occult neurocysticercosis after single taeniacidal dose of praziquantel." Lancet 342 (1993):  748|Leblanc R, Knowles KF, Melanson D, MacLean JD, Rouleau G, Farmer JP "Neurocysticercosis: surgical and medical management with praziquantel." Neurosurgery 18 (1986):  419-27|"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17956, 1510, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17957, 15194, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17958, 15198, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17959, 17726, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17960, 18443, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17961, 25135, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17962, 25136, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17963, 25137, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17964, 26607, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17965, 1510, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17966, 15194, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17967, 15198, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17968, 17726, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17969, 18443, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17970, 25135, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17971, 25136, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17972, 25137, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17973, 26607, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17974, 1510, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17975, 15194, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17976, 15198, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17977, 17726, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17978, 18443, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17979, 25135, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17980, 25136, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17981, 25137, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17982, 26607, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '"Product Information. Biltricide (praziquantel)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17983, 929, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17984, 4136, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17985, 4586, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17986, 4587, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17987, 12996, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17988, 18253, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17989, 18254, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17990, 22272, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17991, 23833, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17992, 26424, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17993, 30132, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17994, 31130, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17995, 929, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17996, 4136, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17997, 4586, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17998, 4587, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17999, 12996, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18000, 18253, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '"Product Information. Citanest Plain (prilocaine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
